MAAsiRNA
PrivateLast Round
Accelerator
Nov 24, 2023
Total Funding Raised
$750,000
Company Overview
MAAsiRNA is a biotechnology company that develops siRNA-based targeted therapies for nervous system pathologies, including Charcot-Marie-Tooth disease type 1A.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
MAAsiRNA Comparables
Compare MAAsiRNA with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Armatus Bio | 86% | |
| Shark Tooth Bio | 84% | |
| Nervosave Therapeutics | 83% | |
MAAsiRNA Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Accelerator | Nov 24, 2023 |
MAAsiRNA Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SATT Paris-Saclay | Accelerator |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 24, 2023
$750K raised, led by SATT Paris-Saclay.
MAAsiRNA Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about MAAsiRNA's valuation, stock price, and market status.